Amgen Shares Sold by KFG Wealth Management

Institutional investor reduces stake in biotech giant

Apr. 7, 2026 at 11:40am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, metallic banking equipment and machinery, conveying the complex financial infrastructure underlying Amgen's stock performance.Institutional investors continue to closely monitor and adjust their positions in biotech giant Amgen.Thousand Oaks Today

KFG Wealth Management LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 37.1% in the fourth quarter, according to the company's latest 13F filing with the SEC. The fund now owns 6,248 shares of the medical research company's stock, down from 9,941 shares previously.

Why it matters

Amgen is one of the world's largest biotechnology companies, with a focus on developing innovative human therapeutics. Changes in institutional ownership can signal shifts in investor sentiment and market dynamics around the stock.

The details

KFG Wealth Management sold 3,693 Amgen shares during the fourth quarter, reducing its total position to 6,248 shares valued at $2,045,000 as of the most recent filing. Other major institutional investors, including Vanguard Group, State Street Corp, Capital International Investors, and Capital Research Global Investors, continue to hold significant stakes in Amgen.

  • KFG Wealth Management filed its 13F report for the fourth quarter of 2025 on April 7, 2026.

The players

KFG Wealth Management LLC

An institutional investment firm that manages assets for clients.

Amgen Inc.

A global biotechnology company that focuses on developing innovative human therapeutics.

Got photos? Submit your photos here. ›

The takeaway

This filing highlights the ongoing shifts in institutional ownership of Amgen, one of the biotech industry's most prominent players. Investors will be watching to see if other major funds follow suit in adjusting their positions in the company.